null

null

null

null

0.70x Total Debt / Equity (Moderate leverage)

~$8-12M annual interest expense increase per 100bps rise; ~$1.4B variable-rate debt exposure makes leverage ratio sensitive to rate environment

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Single-use surgical components from Chinese contract manufacturers; Irish and German collagen/biologics processing facilities face EU regulatory chokepoints

~35% international revenue; EUR depreciation (Europe ~20% revenue), GBP, and AUD represent top devaluation risks; no significant natural hedging disclosed

Primary exposure: Eurozone (~20% revenue), UK (~5%), and Asia-Pacific (~7%); EUR/USD and GBP/USD volatility directly impacts reported revenue and margins

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

No single vendor exceeds 30% of input costs publicly; however, collagen matrix suppliers and titanium mesh fabricators have limited substitutability, creating moderate lock-in risk

Minimal cloud dependency for core operations; medical device manufacturing and hospital contracting are largely on-premise and field-sales driven; 30-day termination manageable

Secondary software/digital health tools (surgical planning) have moderate cloud dependency; disruption would impair sales enablement but not core product delivery

Low API coupling risk; Integra is a hardware/biologics company; ERP (SAP) and CRM integrations exist but are not revenue-critical customer-facing APIs

Revenue model is product sales and service contracts for medical devices; fails Howey Test on all prongs; no securities classification risk

Very High

Moderate GDPR exposure via European patient/hospital data in surgical systems; CCPA exposure limited; MDR compliance in EU adds regulatory overhead beyond pure data risk

Moderate; neurosurgery and regenerative tissue markets are concentrated; FTC scrutiny of medical device M&A (e.g., Orthopedic Implant Company acquisitions) is an ongoing risk

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Approximately 60-65% recurring/contractual (GPO agreements, hospital system contracts, implant pull-through); 35-40% transactional single-procedure sales

Primary: consumable implant and regenerative tissue sales tied to surgical procedures; Secondary: capital equipment placements driving recurring disposables pull-through

GPO and IDN contracts cap pricing flexibility; ASP erosion ~1-3% annually from competitive bidding; premium biologics segment retains stronger pricing power than commoditized implants

6/10; strong in neurosurgery reconstructive niche and regenerative tissue, weak in competitive spine and orthopedic segments under GPO pressure

52.0% Gross Margin (Strong (40-60%))

No meaningful free-rider problem; products require surgeon training and hospital procurement; switching costs are moderate via surgeon preference and stocking commitments

Revenue growth is largely headcount-sublinear at scale; manufacturing has fixed cost leverage, but sales force expansion is partially linear with new territory/product launches

Marginal cost of growth is moderate; incremental revenue in existing accounts is high-margin; new geography or product line requires proportional SG&A and regulatory investment

Not a franchise model; hospital/GPO distributor compliance risk exists but is managed via standard med-device contracting; not material relative to regulatory (FDA/MDR) compliance risk

At 10x scale, CAC efficiency improves via GPO leverage and surgeon network effects; however, hospital consolidation compresses ASPs and may offset volume gains

Weak direct network effects; surgeon training programs and installed base create soft lock-in but not true network effects; durability relies on switching costs, not network dynamics

-15.6% Return on Assets (Negative equity)

Tier 2 (moderate resilience); neurosurgery trauma cases are non-deferrable, but elective reconstructive and spine procedures decline 10-20% in severe recessions

Hospitals and health systems (via GPO contracts); top 10 GPOs represent significant contract concentration; IDN consolidation increases customer concentration risk over time

Neurosurgeons and plastic/reconstructive surgeons as key clinical decision-makers; no single surgeon or hospital system publicly disclosed as >10% revenue; moderate concentration risk

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

5.0% CapEx / Revenue (Low-CapEx Asset-Light)

0000917520

IART